Soft-tissue sarcomas are mesenchymal tumors that respond poorly to systemic chemotherapy. Suicide gene therapy may be an alternative treatment strategy. Here we show a high susceptibility of human sarcoma cell lines for recombinant adeno-associated virus 2 (rAAV-2) suicide vectors: connective tissue sarcoma (HS-1), fibrosarcoma (HT-1080), Ewing sarcoma (RD-ES), Askin tumor (SK-N-MC), rhabdomyosarcoma (A-204) and soft-tissue sarcoma (WSKL-1). Several vectors containing the thymidine kinase (TK) gene under the control of either the cytomegalovirus promoter or the elongation-factor 1 alpha (EF1a) promoter were cloned and tested. Higher expression levels of the transgene were observed in the sarcoma lines when using the EF1a-suicide gene-containing vectors. A complete eradication of rAAV-2-EF1a-TK/eGFP (TK/enhanced green fluorescent protein fusion gene)-transduced tumor cells was shown following exposure to ganciclovir (2.5 mg/ml) in vitro, while at this dose level 490% of mock-transduced tumor cells survived. Xenotransplantation tumor models (intraperitoneal, subcutaneous) for the human sarcoma cell line HS-1 were established in nonobese diabetic/severe-combined immunodeficient mice. Mice transplanted with rAAV-2-EF1a-TK/eGFPtransduced and ganciclovir-exposed tumor cells survived 45 months while in the nontransduced group all mice had died approximately 1 month after inoculation. These data hold promise for further development of rAAV-2-based suicide gene therapy of sarcomas.
S
arcomas are malignant tumors which are derived from mesenchymal tissue. They can appear in the extremities, trunk, retroperitoneal space and in the head. They are rare neoplasms, comprising up to 1% of all malignant tumors of adults. Approximately half of the patients die, mostly due to metastases of the primary tumor, usually within 5 years after diagnosis. While 10% of all sarcoma patients already have metastases at the time of diagnosis, 40-60% of patients with localized, high-grade soft-tissue sarcoma develop metastases, mostly in the lung. The mean survival time from the time of diagnosis runs at 8-12 months. Only a few chemotherapeutic drugs such as doxorubicin and ifosfamide induce responses in more than 15% of patients, 1 while unfortunately, other cytostatics have not shown significant activity in the treatment of sarcoma in adults. 2 Therefore, novel therapy approaches are imperative. One strategy is the use of viral vectors containing suicide genes that are able to kill efficiently the targeted tumor cells. One candidate is the Herpes simplex-derived thymidine kinase (TK) gene, which has been used in several vector systems, for example adeno-, 3, 4 adeno-associated- 5, 6 and retroviral 7, 8 vectors allowing one to kill the infected cells after supplementing the medium with the prodrug ganciclovir. Ganciclovir (GCV) is a nucleoside analog that is phosphorylated by TK to GCV monophosphate and is further phosphorylated by the cellular kinases to GCV diphosphate and GCV triphosphate. GCV triphosphate competes with deoxyguanosine triphosphate for the DNA polymerase and, as a result, DNA synthesis is impaired by chain termination resulting in cell death in the dividing cells. 9 Interestingly, besides the direct and indirect toxicity (bystander effect), an immunotoxic effect has also been observed for the TK/ganciclovir system, the mechanism of which has not been fully elucidated yet. 7, 10 We and others have investigated the infectability of tumor cells by recombinant adeno-associated virus 2 (rAAV-2) vectors. [11] [12] [13] [14] [15] [16] For further reading on TK-mediated gene therapy, please refer to a recent review by Fillat et al. 17 In this study, we investigated the susceptibility of six human sarcoma cell lines to rAAV-2 suicide vectors and the subsequent killing of the infected sarcoma cells following exposure to the prodrug ganciclovir.
Materials and methods

Plasmid DNA production
For the amplification of plasmid DNA the competent E. coli strain DH5a (F-f80lacZDM15 D(lacZYA-arg-F)U169 deoR recA1 endA1 hsdR17(r k À , m k þ ) phoA supE44 thi-1 gyrA96 relA1; Life Technologies, Lofer, Germany) was used. Plasmid DNA was isolated using either the QIAprep Spin Miniprep (subcloning-scale) or the Qiagen EndoFree Plasmid Maxi Kit (transfectionscale; Qiagen, Hilden, Germany) according to the protocol supplied by the manufacturer. The quality and quantity of the plasmid DNA were verified by gel electrophoresis and UV-photospectometry (GeneQuant II, Pharmacia Biotech, Erlangen, Germany).
rAAV-2 vectors
For production of rAAV-2 batches, the following plasmids were used: pDG, 18 pTR-UF5(-CMV-GFP), 19 pTR-UF5-EF1a-GFP, pMRV-CMV-TK/eGFP and pMRV-EF1a-TK/eGFP. pDG, a generous gift from Dr Kleinschmidt (DKFZ, Heidelberg, Germany), is a helper plasmid and provides all genes required for rAAV-2 production in trans. For pTR-EF1a-UF5, the EF1a promoter was excised from pHR-HIV-EF1a 20 by ClaIBamHI digestion, sub-cloned into ClaI-BamHI cut pBlu2KS þ (Stratagene, Heidelberg, Germany) and the EF1a promoter containing KpnI-XbaI fragment was cloned back into a KpnI-XbaI digested pTR-UF5 backbone lacking the CMV sequence. The construct pMRV-CMV-TK/eGFP was produced by replacing the NotI hGFP gene from pTR-UF5 with the NotI-digested TK/ eGFP fusion gene fragment from pTK-eGFP. 21 For generation of pMRV-EF1a-TK/eGFP, the CMV promoter/enhancer sequences from pMRV-CMV-TK/eGFP were excised with KpnI-XbaI, replaced by the EF1a promoter from KpnI-XbaI-digested pTR-UF5-EF1a-GFP and the Neo r -cassette removed by SalI-SalI digestion and religation of the plasmid backbone. The construction of pTR-UF5-LTR-GFP and pTR-UF5-PGK-GFP has been described previously. 22 Nomenclature of virus stocks: all rAAV-2 virus stocks obtained the prefix ''rAAV-2-'', supplemented with the rAAV-2 vector plasmid name as suffix. To enhance clarity, the name of the plasmid backbone was omitted (e.g. an rAAV-2 stock of pTR-UF5-CMV-GFP will be designated rAAV-2-CMV-GFP).
Cells and cell culture
The human embryonic kidney cell line HEK 293 T and the cervix carcinoma line HeLa-RC 23 were grown in DMEM supplemented with 10% fetal calf serum (FCS), penicillin (10 IU/ml) and streptomycin (10 mg/ml), and were kind gifts from Dr. Kleinschmidt. The sarcoma cell lines A-204 (Rhabdomyosarcoma 24 ), HS-1 (epitheloid sarcoma, 25 HT-1080 (fibrosarcoma 26 ), RD-ES (Ewing sarcoma), SK-N-MC (Askin tumor 27 ) and WSKL-1 (uncharacterized sarcoma), were all obtained from the tumor bank of the German Cancer Research Center (DKFZ, Heidelberg, Germany). These cells were grown in RPMI supplemented with 10% fetal calf serum (FCS), penicillin (10 IU/ml) and streptomycin (10 mg/ml). Cells were maintained at 371C/5% CO 2 . The culture media, penicillin and streptomycin were all obtained from Life Technologies, whereas FCS was purchased from Sigma (Deisenhofen, Germany). Note that even though SK-N-MC was originally described as a neuroblastoma, it is now widely regarded as Askin tumor (related to Ewing sarcoma 28 ).
Production, purification and concentration of rAAV-2 batches rAAV-2 particles were produced by two-plasmid transient transfection as described previously. 22 In brief, rAAV-2 particles were released by freeze-thawing (À801-371C; three cycles), cell debris was removed by centrifugation and the supernatants were pooled. The rAAV-containing lysate was concentrated and purified by a modified procedure previously described by Tamayose et al. 29 Briefly, after pre-equilibration with PBS, the lysate was loaded on a column containing 8 ml sulfonated cellulose matrix beads (Cellufine sulfate, Millipore, Eschborn, Germany). rAAV-2 particles were eluted with 10 mM phosphate buffer (pH 7.2) containing 1.0 M NaCl after washing the column thoroughly with PBS. Modification of the protocol: after the freeze-thawing step, a DNase/ RNase and filtration procedure was introduced (modified from Auricchio et al 30 ) . To 50 ml lysate, 0.5 mg of each DNase I and RNase A were added and the sample was incubated for 30 minutes at 371C. After 15 minutes of centrifugation at 2000 g the supernatant was subsequently filtered through a 5 mm and a 0.8 mm pore size filter (both Millipore) and the procedure was continued as mentioned above. The eluted fractions, 4 or 8 ml each, were further purified and concentrated by sucrose-cushion centrifugation. The samples were loaded on top of two layers of sucrose, 50 and 30%, respectively, and centrifuged for 5 hours in a Beckman ultracentrifuge (SW40ti swingoutrotor; Beckman, Mu¨nchen, Germany) at 250,000 g. The viral pellet was resuspended in 1.5 ml Opti-MEM supplemented with 10 IU/ml penicillin and 10 mg/ml streptomycin (both Life Technologies), aliquoted in 250 ml portions and stored at À801C until further use. From each step mentioned above, small aliquots were taken for subsequent titration in order to determine the purification and concentration efficiency of the virus batch.
Functional and real-time quantitative PCR (RQ-PCR) titration of rAAV-2 batches
All rAAV-2 stocks were titrated using both the functional and the novel RQ-PCR titration method, as described previously. 22 Virus titers are given as biologically functional transducing units.
Transduction
At 1 day prior to transduction, cells were seeded into 24-well plates at a density of 2 Â 10 4 cells/well containing 300 ml of their respective media. In all experiments, cells were transduced with rAAV-2 particles at a multiplicity of infection (MOI) as described in the Results section. At 60 hours after infection, cells were harvested, washed with ice-cold PBS and stored at 41C (o15 minutes) until further processing. Any modifications to the transduction conditions are mentioned in the Results section.
Flow cytometric analysis of gene transfer
Acquisition and analysis were performed on a FACSCalibur flow cytometer (Becton-Dickinson) mounted with an air-cooled 488 nm Argon laser using Cellquest software (Becton-Dickinson). GFP was measured on the FL1-channel and plotted against side scatter (SSC). For each cell line, GFP expression was measured against the respective (uninfected mock) control cells, thereby correcting for auto-and unspecific (FL1) fluorescence. Immediately before measurement, dead cells were excluded from the analysis using propidium iodide (10 mg/ ml; Sigma) uptake. The mean fluorescence is given in arbitrary fluorescence units (afu).
MTT assay
The MTT assay, a colorimetric procedure for determining mammalian cell survival and proliferation as described by Mosmann, 31 was used. It is based on the cleavage of the yellow tetrazolium salt 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT; SIGMA) to dark blue formazan crystals by viable cells. A constant fraction of the harvested cells was seeded in a total volume of 100 ml PBS (Life Technologies; all samples at least in duplicates) into 96-well flat-bottomed microtiter plates (Becton-Dickinson); 15 ml of a 5 mg/ml solution of MTT in PBS was added to each well and the plates were incubated for 4 hours at 371C/5% CO 2 . PBS (100 ml) with MTT served as negative control. Thereafter, 100 ml of 10% sodium dodecyl sulfate solution in 0.01 M hydrochloric acid was added to each well in order to solubilize the formazan crystals. After incubating at 371C overnight, the absorbance (A) was measured at 540 nm (reference wavelength 690 nm) with a Multiskan Bichromatic plate reader (Labsystems, Helsinki, Finland) and the data were analyzed using the SeroCalc v3.0 software-package. Cell kill ratios (% surviving cells) were defined as A treated / A untreated Â 100.
Thymidine kinase/ganciclovir cell kill experiments
After transduction, cells were treated with ganciclovir (GCV; Cymeven, Hoffmann-la Roche, Grenzach-Wyhlen, Germany) on day 1. Medium was replaced with fresh GCV-containing medium every third day for up to 14 days. At day 7 and 14 cells were harvested, cell count and viability were determined by MTT assay and FACS analysis of propidium iodide-stained samples. For the day 7 groups, a fraction of the cells was reseeded and cultured for another 7 days with GCV-containing medium. Transduction conditions and respective GCV doses are given in the Results section.
Animals
A breeding colony of nonobese diabetic/severe combined immune deficiency (NOD/SCID) mice was established and maintained at Charles River (Sulzfeld, Germany; breeding stocks originally from Jackson Laboratories, Bar Harbor, ME). During the experiments, the mice were housed at the animal laboratory of the German Cancer Research Center. Mice were kept in isolators under pathogen-free conditions.
Transplantation of human sarcoma cells into NOD/ SCID mice
For determining the optimal dose-effect conditions, HS-1 cells were transplanted into NOD/SCID mice by either intraperitoneal (i.p.; 1 Â 10 4 to 1 Â 10 6 cells/mouse), subcutaneous (s.c.; 1 Â 10 4 to 1 Â 10 6 cells/mouse) or intravenous (i.v.; 1 Â 10 2 to 1 Â 10 5 cells/mouse) route of administration. Mice were killed by cervical dislocation when tumor size measured over 2 cm in diameter or the end of the experiment was reached (as described in the Results section). Post-mortem examination was performed to determine the exact tumor size and the existence of metastases, ascites and/or other possible abnormalities.
Statistics
Data are presented as mean values 71 standard error (SEM). Significance and correlation levels were determined using the (un)paired Student t-test.
Results
To determine the therapeutic potential of rAAV-2 vectors for the treatment of sarcomas, several suicide genecontaining vectors were cloned, six sarcoma cell lines were screened, the ganciclovir prodrug toxicity to parental cells was determined and compared to rAAV-2-transduced sarcomas. Long-term eradication of sarcoma cells by suicide gene therapy was confirmed in a human-mouse sarcoma xenograft model.
Susceptibility of sarcoma cell lines to rAAV-2
To test the effect of several promoters, a set of four rAAV-2 vectors containing different promoters (PGK, LTR, CMV and EF1a) were used to infect HS-1 cells. As shown in Figure 1 , a clear difference in GFP expression could be detected and a significantly higher expression (mean fluorescence intensity; MFI) was observed using EF1a, when compared to the PGK (Po.01), LTR (Po.01) and CMV (Po.05) promoter-containing vectors. In the following experiment, all six sarcoma cell lines were infected with either the rAAV-2-EF1a-GFP or the rAAV-2-CMV-GFP vector, and expression and transduction rates were determined by FACS. For all cell lines tested a high transgene expression could be observed (Table 1) . For example, the product between the %GFP þ and MFI for HS-1 cells transduced with the EF1a vector was significantly higher than for HS-1 cells transduced with a vector containing the CMV promoter (CMV: 1639372324 versus EF1a: 3177772309; Po.05). For this reason the EF1a promoter was used in further experiments.
Titration of ganciclovir on sarcoma cell lines
To determine the optimal and maximal nontoxic dose, four parental sarcoma cell lines HS-1, HT-1080, RD-ES and SK-N-MC were treated with ganciclovir doses ranging from 0 to 25 mg/ml for 2 weeks, and the growth inhibition was determined using the MTT assay (Table 2 ). Since ganciclovir is activated by TK to an antimetabolite, which leads to blockage of DNA synthesis in replicating cells only, experiments were conducted for 7 and 14 days. Lines A-204 and WSKL-1 showed erratic growth characteristics, especially at low and high cell concentrations, and were therefore not assessable. A nontoxic dose (Table 2 ) of 2.5 mg/ml ganciclovir resulting in survival of 480% parental cells was used for all further experiments.
rAAV-2-based suicide gene therapy for sarcoma cell lines
At day 0 the sarcoma cells were infected with rAAV-2-EF1a-TK/eGFP at an MOI of 200 and the next day treated with ganciclovir at 2.5 mg/ml. At day 7 and day 14, MTT-assays were performed to determine cell counts and compared with the respective parental cell line. This experiment was performed three times for each of the sarcoma lines using rAAV-2-EF1a-TK/eGFP. Whereas at day 7 some tumor cells were still adhering to the culture dish surface, these cells did not divide any more (microscopic observations) and took up propidiumiodide as assessed by FACS. This suggests that the residual cells were indeed affected by the activated prodrug, which was confirmed by the day 14 data (Fig  2) . At this point no surviving cells could be observed anymore, whereas cells in the control groups were generally unaffected.
Human sarcoma xenograft NOD/SCID mouse model
The human sarcoma cells (line HS-1) were transplanted using three routes of administration: intravenous (i.v.), subcutaneous (s.c.) and intraperitoneal (i.p.) For each route, several cell numbers were tested to determine the Figure 1 Effect of different promoters on the expression level of GFP in the sarcoma cell line HS-1. HS-1 cells were infected using several rAAV-2 vectors containing different promoters (CMV, EF1a, LTR and PGK) at an MOI of 100 and expression levels were shown in a FACS histogram overlay plot. A significantly higher GFP-mean fluorescence intensity (MFI) was observed using the EF1a-containing vectors compared to the PGK (Po.01), LTR (Po.01) and CMV (P ¼ .04) vectors (n ¼ 3). Sarcoma cells were transduced with an rAAV-2-GFP vector containing either the CMV or EF1a promoter. The transduction and expression levels were determined by FACS analysis at day 3. MFI ¼ Mean fluorescence intensity (in arbitrary units).
minimal required cell number for each tumor line to be able to kill the mouse within a certain time frame (o5 months). While both an i.p. and s.c. tumor model could be established (Table 3) , the i.v. route did not yield any tumors, independent of the amount of tumor cells transplanted.
For the s.c. and i.p. route of transplantation, a doseeffect relationship could be observed, where more cells resulted in a shorter survival. For HS-1, the i.p. route was more efficient than the s.c. route and resulted in rapid tumor engraftment and growth. Also these tumors were highly metastatic following i.p. transplantation. Therefore, this route of administration was chosen in further experiments.
Animals were transplanted with rAAV-2-EF1a-TK/ eGFP and ganciclovir-treated HS-1 cells. The HS-1 sarcoma line was chosen, because of its rapid engraftment and growth at very low cell numbers in the NOD/SCID mice. The animals survived until the end of the experiment (4150 days; Figure 3 ) without any signs of tumor development (as confirmed by post-mortem examination), whereas the animals that received either untransduced HS-1 cells or untransduced GCV-treated HS-1 cells died approximately 30 days after transplantation.
Discussion
We show that rAAV-2 vectors efficiently transduce a wide range of soft-tissue sarcoma cell lines. With rAAV-suicide vectors cloned in our laboratory, we were able to eradicate completely all sarcoma cells of the cell lines used. Further, a human sarcoma mouse xenograft model was established and the efficacy of the rAAV-2 -TK/ ganciclovir system (ex vivo treatment) was demonstrated in a proof-of-principle experiment.
Susceptibility of sarcoma cells to rAAV-2 vectors
In previous experiments, 15, 16 where several tumor cell lines were screened for susceptibility to infection with rAAV-2, we were able to show the highest infection rates and expression of an AAV-2 vector containing the GFP marker gene in soft-tissue sarcoma cells. Therefore, in this study the susceptibility of sarcoma cells was further investigated. Five additional soft-tissue sarcoma cell lines (fibrosarcoma line HT-1080, Ewing sarcoma line RD-ES, Askin tumor line SK-N-MC, rhabdomyosarcoma line A-204 and soft-tissue sarcoma line WSKL-1) were tested, all displaying high transduction rates and expression of the vector, providing additional evidence for our hypothesis of a generally high susceptibility of soft-tissue sarcoma cells for transduction by rAAV-2. In order to obtain the highest expression of the transgene, the expression level of a total of four AAV-2 vectors containing the PGK, LTR, CMV or EF1a promoter sequences was assessed using the HS-1 line. All vector stocks were titrated using both a functional and a real-time PCR-based 22 assay to ensure MOI consistency for all vectors. A significantly higher Cells were treated with GCV doses ranging from 0 to 25 mg/ml and grown for 2 weeks. At days 7 and 14, growth was determined and inhibition was calculated. For all cell lines, a dose of 2.5 mg/ml GCV (480% survival) was used in the rAAV-2 suicide cell kill experiments. GFP level was observed using the EF1a-containing vectors compared to the PGK (Po.01), LTR (Po.01) and CMV (Po.05) vectors (Fig 1) . The superiority of the EF1a promoter was further confirmed in additional experiments for each of the six sarcoma cell lines when compared to the CMV promoter (Table 1) . For this reason, the EF1a was the promoter of choice in further experiments.
When determining the susceptibility of all six tested sarcoma lines for the rAAV-2-EF1a-GFP vector, over 50% GFP þ cells could be observed at an MOI of 100 (range: 55.771.8-93.770.2). Previous data suggest that an increase in the MOI will also result in a further increase in the rate of transduction. 15, 16 Vector construction strategies for rAAV-2 suicide gene therapy
In order to perform suicide gene therapy, vectors that contained a suicide gene were cloned. The herpes simplex thymidine kinase gene was chosen. 9 Furthermore, an additional marker gene (GFP) was chosen that allows to monitor transduced cells during subsequent cell kill experiments. Besides the GFP-containing vector pTR-UF5-EF1a-GFP, two suicide vectors, pMRV-CMV-TK/ eGFP and pMRV-EF1a-TK/eGFP, were cloned, which contained the TK-eGFP fusion gene. 21 It has been shown that both the TK and the GFP gene were fully functional, allowing for both cell kill and marker studies, simultaneously.
Efficiency of rAAV-2-based suicide gene therapy for sarcomas
Before starting in vitro experiments, the intrinsic toxicity of the prodrug had to be determined. While the HT-1080 line survived ganciclovir concentrations above 10 mg/ml without any proliferation inhibition, the other three cell lines were more sensitive. A concentration of 2.5 mg/ml was well tolerated by all the sarcoma lines and therefore used in the in vitro cell kill experiments. In the literature, nontoxic ganciclovir doses are reported as ranging from 0.1 to 10 mg/ml, depending on the target cells. [32] [33] [34] This shows that toxicity tests are necessary for each new type of target cell in order to avoid false-positive results due to intrinsic toxicity.
Whereas in the literature (Beltinger et al, 32 Koshikawa et al, 33 Miyauchi et al, 34 Rivas et al 35 ) a wide range of incubation periods are described, a 14-day experiment was expected to be sufficient to allow full eradication of rAAV-2-EF1a-TK/eGFP-infected cells by TK/ganciclovir induced cytotoxicity. This was indeed observed for all four sarcoma lines (Fig 2) after 14 days, although even after 7 days in most groups less than 10% of the tumor cells were left. It should be noted that even though these cells were still adherent at day 7, they were unable to divide as observed by light microscopy, thereby losing their tumorigenicity/cloning ability. As shown by FACS analysis, these cells also took up propidium iodide. At day 14, no cells could be observed anymore in the rAAV-2-EF1a-TK/eGFP þ ganciclovir-treated groups. As shown in Figure 2 , an increase in cell count could be observed for the SK-N-MC and cells treated with GCV, which might be caused by RD-ES growth induction of the cells by subtoxic doses of GCV.
The data presented here show that rAAV-2 suicide gene-containing vectors are indeed able to infect and eradicate sarcoma cells efficiently.
A last requirement for in vivo rAAV-2 suicide vector gene therapy is the availability of an in vivo sarcoma model. For this purpose, NOD/SCID mice were used, which have a homozygous mutation in the severe combined immunodeficiency (SCID) gene resulting in a block in T-and B-lymphocyte development, 36 which allows the transplantation and growth of normal and malignant human cells. [37] [38] [39] An optimal in vivo tumor model should offer a short transplantation-to-tumor time, constant and highly efficient tumor development, mimic the tumor progress and metastatic capabilities as observed in tumor patients and require low amounts of cells. The three most common transplantation routes were tested: i.v., s.c. and i.p. An efficient and constant in vivo tumor model was obtained using the HS-1 sarcoma line. Except for the i.v. route of transplantation, it was highly tumorigenic using the s.c. and i.p. administration, with the i.p. route even at very low concentrations (1 Â 10 4 NOD/SCID mice were transplanted with HS-1 cells at day 0 either administered by i.p. or s.c. route. Mouse status was checked twice a week until the end of the experiment. As an endpoint a tumor size over 2 cm in diameter or the death of the mice was recorded. Post-mortem examination was performed to confirm tumor growth and status. cells). This means that less virus is needed for efficient gene transfer and cell kill. An additional feature of the HS-1 cells is the generation of metastases, which is often observed in sarcoma patients.
In a proof-of-principle in vivo experiment, where mice were transplanted with ex vivo treated sarcoma cells (HS-1 cells with rAAV-2-TK/eGFP and GCV), tumor-free survival 45 months was obtained while control animals transplanted with parental HS-1 cells died after approximately 30 days.
The results of this study are the first steps towards a new method of treating patients who suffer from softtissue sarcoma, a disease with often dismal prognosis.
